Climb Bio Equity Growth

What does Climb Bio do? Eliem Therapeutics, Inc. develops novel therapies for neuronal excitability disorders, targeting unmet needs in psychiatry, epilepsy, chronic pain, and nervous system disorders. Its lead product ETX-123, a Kv7.2/3 potassium channel opener, is designed to improve safety and tolerability over earlier molecules while leveraging clinically validated mechanisms. The company focuses on validated mechanisms of action with therapeutic potential for patients with these conditions. ETX-123 is a generate new chemical entities candidate that harnesses the efficacy of Kv7.2/3 channel mechanism, with encouraging clinical data in depression, epilepsy, and pain. The company's pipeline includes clinically differentiated product candidates targeting validated therapeutic targets to deliver improved therapeutics. Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Wilmington, Delaware, with 30 full-time employees. The company's revenue model is not disclosed in the business description, as it is a clinical-stage biotechnology firm focused on research and development rather than commercial product sales. Its primary focus is on advancing its pipeline through clinical trials to achieve regulatory approvals and potential future partnerships or sales. Climb Bio is one of the most popular companies on Eulerpool.